Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease

Next Previous
Trial Profile

A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brodalumab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen

Most Recent Events

  • 30 Nov 2021 The primary endpoints have been changed from Crohn's Disease Activity Index, Harvey Bradshaw Index, Adverse events, and Change in laboratory parameters to Number of Participants With Treatment-emergent Adverse Events, Percentage of Participants Who Achieved a CDAI Response, Percentage of Participants Who Achieved Clinical Remission, according to ClinicalTrials.gov record.
  • 24 May 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top